

Letter No.: GLHRL/09/2025-25
Date: April 28, 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIPT CODE: 543520
ISIN: INE0J2K01014

Subject: Outcome of Meeting of Board of Directors held today i.e. Monday, April 28, 2025, in terms of Regulation 30 of SEBI (LODR) Regulations, 2015, for Consideration and approval of Audited Financial Results for the Half Year and Year ended on March 31, 2025.

Dear Sir/Madam,

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that in the Board Meeting held today (i.e. Monday, April 28, 2025), the Board of Directors of the Company has considered and approved the Audited Financial Results for the Half Year and Year ended March 31, 2025 along with the Audit Report.

The above matter has been duly approved by the Board of Directors at their meeting which commenced at 12:00 P.M. and concluded at 02:15 P.M.

We would like to inform you that M/s, R B Gohil & CO., Chartered Accountants, Statutory Auditors have issued their Audit Reports with unmodified opinion on Audited Financial Results for the year ended March 31, 2025

In this connection, we are enclosing herewith Audited Financial Results for the Half year and Year ended on March 31, 2025, Audit Report and the declaration that Auditor's Report on the results is with unmodified opinion (as Annexure-1) for your information and record.

The same will be made available on the Company's website www.globalhospital.co.in.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

DHRUV
SURESHKU
MAR JANI
Dhruv Jani
Managing Director
DIN: 03154680

Digitally signed by
DHRUV
SURESHKUMAR JANI
Date: 2025.04.28
14:19:15 +05'30'

Encl: a/a

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India

Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;

Letter No.: GLHRL/10/2025-26
Date: April 28, 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIPT CODE: 543520
ISIN: INE0J2K01014

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 33(3)(d) of the Listing Regulations, as amended from time to time, we hereby declare that Statutory Auditor of Global Longlife Hospital and Research Limited, M/s, R B Gohil & CO., Chartered Accountants (Firm Registration Number: 119360W), have submitted their Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended March 31, 2025, as approved by the Board at its Meeting held on April 28, 2025.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

DHRUV
SURESHKU
MAR JANI
Dhruv Jani
Managing Director
DIN: 03154680

Digitally signed by
DHRUV
SURESHKUMAR JANI
Date: 2025.04.28
14:20:39 +05'30'

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India
Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;



R. B. Gohil & Co.

Chartered Accountants

Independent Auditors' Report on Financial Results of GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
Global Longlife Hospital and Research Limited

Opinion

We have audited the accompanying Financial Results of Global Longlife Hospital and Research Limited (hereinafter referred to as the "Company") for the half year and year ended 31st March, 2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"),

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- a) are presented in accordance with the Listing Regulations in this regard; and
- b) Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other financial information for the half and year ended 31st March, 2025.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act. and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion.



1st Floor, K.P. Shah House-1, K.V. Road, Jamnagar-361001 M.: 9426478227 Email : rbgohil.gj@gmail.com

BRANCHES : KHAMBHALLIA - PORBANDAR - AHMEDABAD



R. B. Gohil & Co.

Chartered Accountants

Management's and Board of Directors' Responsibilities for the Financial Results

These accompanying financial results have been prepared on the basis of the financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these accompanying Half Yearly and Annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the accompanying Financial Results

Our objectives are to obtain reasonable assurance about whether the accompanying financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these accompanying annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:



1St Floor, K.P. Shah House-1, K.V. Road, Jamnagar-361001 M.: 9426478227 Email : rbgohil.gj@gmail.com

BRANCHES : KHAMBHALLIA - PORBANDAR - AHMEDABAD



R. B. Gohil & Co.

Chartered Accountants

- Identify and assess the risks of material misstatement of the accompanying annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the accompanying financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the accompanying annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the accompanying financial results, including the disclosures, and whether the accompanying financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all





R. B. Gohil & Co.

Chartered Accountants

Relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The accompanying financial results include the results for the half year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2024 of the current financial year.

Parallel, the accompanying financial results include the results for the half year ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year and the audited year to date figures up to the first half year ended as on 30th September, 2023 of the previous financial year.

For, M/s. R B Gohil & Co.
Chartered Accountants
FRN No. 119360W

The circular stamp contains the text: 'R.B. GOHIL & Co.', 'Jamnagar', 'M:104997', and 'Chartered Accountants'.

CA Raghubha B. Gohil
Partner
M.No. 104997
UDIN: 25104997BMGERW3656

Place: Jamnagar
Date: 28th April, 2025

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
CIN : L85110GJ2012PLC068700

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND YEAR ENDED ON MARCH 31, 2025

(Rs. in Lakhs except per share data)

Sr. No.	Particulars	Half Year Ended		Year Ended	
		31-03-25	30-09-24	31-03-24	31-03-25
		Audited	Unaudited	Audited	Audited
1	INCOME				
	Revenue from Operations	0.00	57.73	118.45	57.73
	Other Income	(67.36)	568.97	4.23	501.61
	Total Income	(67.36)	626.70	122.69	559.34
2	EXPENSES				
	Direct Expenses	66.64	116.01	156.87	182.65
	Purchase of Stock-in-Trade	-	-	0.61	-
	Changes in inventories of finished goods, work in progress and stock in trade	0.00	43.72	85.71	43.72
	Employee benefits expenses	70.50	43.08	118.40	113.58
	Finance Costs	0.06	27.56	36.32	27.62
	Depreciation and amortisation expenses	(0.19)	48.38	63.52	48.19
	Other Expenses	(103.01)	236.67	58.80	133.66
	Total Expenses	34.00	515.42	520.23	549.42
3	Profit/(Loss) before exceptional and extraordinary items and tax (1 - 2)	(101.36)	111.28	(397.55)	9.92
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before extraordinary item and tax (3 - 4)	(101.36)	111.28	(397.55)	9.92
6	Extraordinary Items	-	-	-	-
7	Profit/(Loss) before tax (5 - 6)	(101.36)	111.28	(397.55)	9.92
8	Tax Expense				
	a) Current tax	2.58	-	(28.54)	2.58
	b) Deferred tax	0.05	(12.58)	(47.26)	(12.53)
	c) Excess/(Short) Provision Of Income Tax	-	-	-	-
9	Net Profit/(Loss) from continuing activities after tax (7 - 8)	(103.99)	123.86	(321.75)	19.87
10	Net Profit/(Loss) from discontinued operations before tax	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-
12	Net Profit/(Loss) from discontinued operations after tax (10-11)	-	-	-	-
13	Net Profit/(Loss) for the period after tax (9 + 12)	(103.99)	123.86	(321.75)	19.87
14	Other Comprehensive Income, net of tax (OCI)				
	a) Items that will not be reclassified to profit or loss				
	b) Income tax relating to items that will not be reclassified to profit or loss				
	Total				
15	Total Comprehensive Income for the period (13+14)	(103.99)	123.86	(321.75)	19.87
16	Details of Equity Share Capital				
	Paid-up Equity Share Capital	1,050.00	1,050.00	1,050.00	1,050.00
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00
17	Reserves excluding revaluation reserves				
				1,628.88	1,543.14
18	Basic earning (loss) per share (Not Annualised for half year ended)	(0.99)	1.18	(3.06)	0.19
19	Diluted earning (loss) per share (Not Annualised for half year ended)	(0.99)	1.18	(3.06)	0.19
	Debt Equity Ratio	-	-	0.49	-
	Debt Service Coverage Ratio	-	0.43	(11.08)	0.17
	Interest Service Coverage Ratio	-	28.04	(24.38)	10.84

For, Global Longlife Hospital and Research Limited

Dhruv S. Jani
Managing Director
DIN: 03154680



Date: 28/04/2025
Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
CIN : L85110GJ2012PLC068700

AUDITED STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST MARCH, 2025

(Rs. in Lakhs)

	Particulars	As At 31-03-2025	As At 31-03-2024
		Audited	Audited
	Equity and liabilities		
1	Shareholders' funds		
	Share capital	1,050.00	1,050.00
	Reserves and surplus	1,628.88	1,543.14
	Money received against share warrants		
	Total shareholders' funds	2,678.88	2,593.14
2	Share application money pending allotment		
3	Deferred government grants		
4	Minority interest		
5	Non-Current Liabilities		
	Long-term borrowings		340.97
	Deferred tax liabilities (net)		-
	Other long-term liabilities		0.89
	Long-term provisions		4.81
	Total Non-Current Liabilities	-	346.67
6	Current Liabilities		
	Short-term borrowings		932.71
	Trade Payables		
	(A) Total outstanding dues of micro enterprises and small enterprises.		62.94
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises.		192.94
	Other current liabilities	1.20	42.70
	Short-term provisions	4.38	1.94
	Total current liabilities	5.58	1,233.23
	Total equity and liabilities	2,684.46	4,173.04

	Assets		
1	Non-current assets		
(i)	Fixed assets		
	Tangible assets		1,725.70
	Intangible assets		1.30
	Tangible assets capital work-in-progress		-
	Intangible assets under development or work-in-progress		
	Total fixed assets	-	1,727.00
(ii)	Non-current investments	3.00	3.00
(iii)	Deferred tax assets (net)	234.78	222.25
(iv)	Long-term loans and advances	-	-
(v)	Other non-current assets	182.95	1,828.52
	Total non-current assets	420.73	2,053.77
2	Current assets		
	Inventories	-	43.72
	Trade receivables	32.12	194.60
	Cash and cash equivalents	2,149.18	38.54
	Short-term loans and advances	26.36	108.96
	Other current assets	56.07	6.45
	Total current assets	2,263.73	392.27
	Total assets	2,684.46	4,173.04

For, Global Longlife Hospital and Research Limited


 Dhruv S. Jani
 Managing Director
 DIN: 03154680

Date: 28/04/2025
 Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN : L85110GJ2012PLC068700


AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED ON MARCH 31, 2025

[Amount in Lakhs]

	Particulars	Year Ended	
		31-03-25	31-03-24
1	Statement of cash flows		
	Cash flows from used in operating activities		
	Profit before extraordinary items and tax	9.92	(226.59)
2	Adjustments for reconcile profit (loss)		
	Adjustments to profit (loss)		
	Adjustments for finance costs	27.62	76.83
	Adjustments for depreciation and amortisation expense	48.19	125.01
	Adjustments for loss on sale of Fixed Asset	(431.18)	5.83
	Net Loss/(Gain) on Sale of Investments	(57.12)	-
	Other adjustments for non-cash items	67.79	57.58
	Change in Reserve & Surplus	65.86	(3,617.02)
	Total adjustments to profit (loss)	(278.83)	(3,351.77)
3	Adjustments for working capital		
	Adjustments for decrease (increase) in inventories	43.72	37.83
	Adjustments for decrease (increase) in trade receivables	162.48	775.09
	Adjustments for decrease (increase) in other assets	1,637.42	2,157.84
	Adjustments for increase (decrease) in trade payables	(255.88)	124.79
	Adjustments for increase (decrease) in other current liabilities	(42.39)	(5.26)
	Adjustments for provisions	(4.94)	(3.49)
	Total adjustments for working capital	1,540.41	3,086.80
	Total adjustments for reconcile profit (loss)	1,261.57	(264.97)
	Net cash flows from (used in) operations	1,271.50	(491.56)
	Dividends received	(0.45)	(1.50)
	Interest received	(12.59)	(4.44)
	Income taxes paid (refund)	26.38	9.72
	Net cash flows from (used in) operating activities before extraordinary items	1,232.07	(507.22)
	Proceeds from extraordinary items		
	Payment for extraordinary items		
	Net cash flows from (used in) operating activities	1,232.07	(507.22)

4	Cash flows from used in investing activities		
	Other cash receipts from maturity of term deposits	(0.28)	8.04
	Investment in Term Deposits		
	Proceeds from Sale of Equity Instruments		7.00
	Purchase of Mutual Funds	(1,850.00)	
	Proceeds from Sale / Redmption of Mutual Funds	1,907.12	
	Proceeds from sales of property, plant and equipment	2,117.23	2.15
	Purchase of property, plant and equipment	(7.24)	(104.89)
	Dividends received	0.46	1.50
	Interest received	12.59	4.44
	Net cash flows from (used in) investing activities before extraordinary items	2,179.88	(81.75)
	Proceeds from extraordinary items		
	Payment for extraordinary items		
	Net cash flows from (used in) investing activities	2,179.88	(81.75)
5	Cash flows from used in financing activities		
	Proceeds from issuing shares		
	Proceeds from Long term borrowings		
	Proceeds from Short term borrowings		389.60
	Repayments of Short term borrowings	(932.71)	(22.14)
	Repayments of Long term borrowings	(340.97)	(23.26)
	Dividends paid		
	Interest paid	(27.62)	(76.83)
	Income taxes paid (refund)		
	Other inflows (outflows) of cash		
	Net cash flows from (used in) financing activities before extraordinary items	(1,301.30)	267.37
	Proceeds from extraordinary items		
	Payment for extraordinary items		
	Net cash flows from (used in) financing activities	(1,301.30)	267.37
	exchange rate changes	2,110.64	(321.61)
6	Effect of exchange rate changes on cash and cash equivalents		
	Effect of exchange rate changes on cash and cash equivalents		
	Net increase (decrease) in cash and cash equivalents	2,110.64	(321.61)
	Cash and cash equivalents cash flow statement at beginning of period	38.54	360.15
	Cash and cash equivalents cash flow statement at end of period	2,149.19	38.54

For, Global Longlife Hospital and Research Limited



 Dhruv S. Jani
 Managing Director
 DIN: 03154680

Date: 28/04/2025
 Place: Ahmedabad

4	Cash flows from used in investing activities		
	Other cash receipts from maturity of term deposits	(0.28)	8.04
	Investment in Term Deposits		
	Proceeds from Sale of Equity Instruments		7.00
	Purchase of Mutual Funds	(1,850.00)	
	Proceeds from Sale / Redmption of Mutual Funds	1,907.12	
	Proceeds from sales of property, plant and equipment	2,117.23	2.15
	Purchase of property, plant and equipment	(7.24)	(104.89)
	Dividends received	0.46	1.50
	Interest received	12.59	4.44
	Net cash flows from (used in) investing activities before extraordinary items	2,179.88	(81.75)
	Proceeds from extraordinary items		
	Payment for extraordinary items		
	Net cash flows from (used in) investing activities	2,179.88	(81.75)
5	Cash flows from used in financing activities		
	Proceeds from issuing shares		
	Proceeds from Long term borrowings		
	Proceeds from Short term borrowings		389.60
	Repayments of Short term borrowings	(932.71)	(22.14)
	Repayments of Long term borrowings	(340.97)	(23.26)
	Dividends paid		
	Interest paid	(27.62)	(76.83)
	Income taxes paid (refund)		
	Other inflows (outflows) of cash		
	Net cash flows from (used in) financing activities before extraordinary items	(1,301.30)	267.37
	Proceeds from extraordinary items		
	Payment for extraordinary items		
	Net cash flows from (used in) financing activities	(1,301.30)	267.37
	exchange rate changes	2,110.64	(321.61)
6	Effect of exchange rate changes on cash and cash equivalents		
	Effect of exchange rate changes on cash and cash equivalents		
	Net increase (decrease) in cash and cash equivalents	2,110.64	(321.61)
	Cash and cash equivalents cash flow statement at beginning of period	38.54	360.15
	Cash and cash equivalents cash flow statement at end of period	2,149.19	38.54

For, Global Longlife Hospital and Research Limited

Dhruv S. Jani
Managing Director
DIN: 03154680



Date: 28/04/2025
Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India CIN: L85110GJ2012PLC068700, Tel No.: (+91) 7211104280; Email: info@globalhospital.co.in; Website: www.globalhospital.co.in

- 1) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on 28th April, 2025.
- 2) The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- 3) The company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under AS - 17 Segment Reporting.
- 4) The accompanying financial results include the results for the half year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2024 of the current financial year.

Parallel, the accompanying financial results include the results for the half year ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year and the audited year to date figures up to the first half year ended as on 30th September, 2023 of the previous financial year.

- 5) Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.
- 6) As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015.
- 7) The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
- 8) The results for the half year and year ended 31st March 2025 are available on the BSE Limited website (URL: www.bseindia.com) and also on the company's website (URL: www.globalhospital.co.in)
- 9) As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting has been made in this regards.

